Results 131 to 140 of about 112,843 (300)

Identification of antibiotic allergies in children using prescribing patterns in the electronic medical record

British Journal of Clinical Pharmacology, EarlyView.
Background By age three, 5%–75% of children have a documented antibiotic allergy (AL). Despite this prevalence, recognition remains low because of limited clinician knowledge and time. Our study evaluates a novel approach to identifying AL using electronic medical record (EMR) prescription patterns.
Georgia Koutsaplis, Kailey Tang, Renee Dimond, Alice Lei, Amanda Wilkins, Amanda Gwee   +5 more
wiley   +1 more source

Voclosporin‐induced gingival enlargement: A case report

Clinical Advances in Periodontics, EarlyView.
Abstract Background Drug‐influenced gingival enlargement (DIGE) is a recognized adverse effect of certain medications, particularly immunosuppressants like cyclosporin and tacrolimus. However, there have been no documented cases of DIGE associated with voclosporin, a newer calcineurin inhibitor used primarily to treat lupus nephritis.
Francesca Racca, Jessica M. Greco, Dimitris N. Tatakis   +2 more
wiley   +1 more source

Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis

Clinical Pharmacology &Therapeutics, EarlyView.
In patients with systemic lupus erythematosus (SLE), increased type I interferon signaling is associated with increased disease activity across organs, including in the kidney, which can cause lupus nephritis (LN). Anifrolumab, which abrogates type I interferon signaling, is an approved treatment for moderate to severe SLE.
Joachim Almquist, Yen Lin Chia, Raj Tummala, Lynn Bertagnolli, David Jayne, Weifeng Tang, Catharina Lindholm   +6 more
wiley   +1 more source

A Pathway to High Quality Clinical Trials in IgA Vasculitis Nephritis: Meeting Proceedings From a Multiprofessional International Collaborative Workshop

Kidney International Reports
IgA vasculitis (IgAV) is an autoimmune disease that affects the small vessels of the skin, joints, gastrointestinal (GI) tract, and kidneys. In the long term, IgAV associated with nephritis (IgAV-N) can progress to kidney failure. Evidence-based clinical
Louise Oni, Rona Smith, Seza Ozen, Chloe Williams, Elin Davies, Charlotte King, Paul Brogan, Mark Haas, Jonathan Barratt, Jeffrey Hafkin, Despina Eleftheriou, Karuna Keat, EMD Smith, Wen Ding, Chee Cheung, Caroline Platt, Evangéline Pillebout, Andrew Chetwynd, Areefa Alladin, Augusto Vaglio, Caroline Jones, Clare Pain, Cord Sunderkötter, John Peipert, Emily Barnes, Giorgio Trivioli, Hayley Hardwick, Henry Morgan, Ingeborg Bajema, James Wason, Joshua Wade, Judith Sanchez-Manubens, Kelly Vernon, Lisa Willcocks, Lorraine Harper, Lowena Lindsay, Madalina Andreea Beldie, Matko Marlais, Michelle O’Shaughnessy, Panagoula Gkargkoula, Patrick Hamilton, Reima Bakry, Roxana Bogos, Selcan Demir, Silke Brix, Simone Appenzeller, Tarun Bansal, Zoi Anastasa, Stephen David Marks, Alexandra Audemard-Verger, Thomas Renson, Marija Jelusic, David Jayne, Alan Salama   +53 more
doaj   +1 more source

METHICILLIN NEPHRITIS

Medicine, 1977
J, Ditlove, P, Weidmann, M, Bernstein, S G, Massry   +3 more
openaire   +2 more sources

Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor, Takanobu Nadai, Kei Irie, Wen Rui Tan, Sanjana Parikh, Anhar Hosawi, Matthijs W. van Hoogdalem, Ronaldo Morales Junior, Sonya Tang Girdwood, Abbie D. Leino, Kana Mizuno, Alexander A. Vinks, Tomoyuki Mizuno   +12 more
wiley   +1 more source

Clinical efficacy and safety of rituximab in lupus nephritis

, 2019
Zhiqing Zhong,1,* Hongyan Li,2,* Hongzhen Zhong,1 Tianbiao Zhou1 1Department of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, 515041 Shantou, China; 2Department of Nephrology, Huadu District People’s Hospital of ...
Li H, Zhou T, Zhong H, Zhong Z
core  

Promising Experimental Treatments for Lupus Nephritis: Key Talking Points and Potential Opportunities

, 2023
Ana Neves,1 Luísa Viveiros,2 Veronica Venturelli,3 David A Isenberg4 1Internal Medicine Department, Centro Hospitalar Universitário de São João, Oporto, Portugal; 2Internal Medicine Department, Centro Hospitalar Universitário de Santo António, Oporto ...
Neves A, Isenberg DA, Venturelli V, Viveiros L   +3 more
core  

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source

Immune checkpoint inhibitor-induced nephrotic syndrome: a pharmacovigilance analysis of 404 FAERS cases and literature case series

Renal Failure
Immune checkpoint inhibitor (ICI)-related nephrotic syndrome is a rare but increasingly reported adverse event, where early-onset severe cases warrant heightened vigilance. This pharmacovigilance study assessed this correlation by analyzing the U.S. Food
Jingjing Ye, Jiangfeng Huang, Leping Shao, Zhi Wang   +3 more
doaj   +1 more source